Established in 1994, HyTest Ltd is a recognized producer of high-quality monoclonal antibodies and antigens for the diagnostic industry all around the world. Building on a strong scientific basis, HyTest has become the global market leader in supplying certain reagents. With several products appointed as the best in the world.
HyTest is a company with an excellent track record and is known for its uncompromising quality. This quality extends to the whole wide product range. See HyTest introduction video below:
Continuous investments in R&D ensure a constant flow of new, even better reagents for the customers. That’s why most of the major diagnostic companies rely on HyTest’s ability to supply the best reagents in the world.
To make customers life easier, HyTest provides comprehensive customer support and user data service for both industrial and research applications. Information is also available at HyTest’s web site as well as in the special brochures. HyTest’s TechNotes offer more information about the products and their applications.
In 2011 HyTest opened an office in Shanghai Zhangjiang Hi-Teck Park. This is only our initial step in expanding our operations in China and in future we will develop our operations even further in order to provide a full portfolio of services in China.
You can visit HyTest China website here: www.hytestchina.com
HyTest has total understanding of the needs of both industrial and research communities. This is one of the reasons why HyTest is able to create success also for its customers.
HyTest Online Store makes your ordering process easier and faster. You will get prices immediately without needing to wait for quotes, so you can proceed to order whenever you need. This will save your valuable time.
You can create your account here.
MSc in Chemistry from NTNU in Trondheim, Norway and PED from IMD in Lausanne, Switzerland
Dr. Apple has served as a Non-Executive Director at HyTest since 2016. Dr. Apple is Medical Director of Clinical Laboratories at Hennepin County Medical Center in Minneapolis, Minnesota, and Professor of Laboratory Medicine and Pathology at the University of Minnesota School of Medicine, Minnesota, USA.
He is one of the key opinion leaders in the field of cardiovascular disease biomarker research. Furthermore, he has either authored or co-authored over 250 scientific papers and has served as an Associate Editor of Clinical Chemistry for over 20 years.
Dr. Apple is a member of the ‘AACC Academy/National Academy of Clinical Biochemistry’ Laboratory Practice committee, the ‘Global Task Force of the Universal Definition of Myocardial Infarction’, the ‘Institute of Medicine’s Committee on Qualification of Biomarkers as Surrogate Endpoints of Chronic Disease Risk’, the ’NHLBI Working Group for Onsite Tools and Technologies for Clinical Cardiovascular Research and Point-of-Care Testing’, and is the Chair of the IFCC "Committee on Clinical Application of Cardiac Biomarkers ", all which have been instrumental in establishing clinical and laboratory practice guidelines for the use of biomarkers for acute coronary syndromes and heart failure.
Possessing broad experience in cardiac diagnostics as a clinicial scientist and as a highly respected researcher, Professor Apple brings important insights to the HyTest Board of Directors.
Dr. Severina is the Managing Director of HyTest. Prior to joining HyTest, she worked as a Senior Researcher at the Moscow State University and she moved to Finland in order to join Hybritest project at the University of Turku in 1993. In 1994, Hybritest was reorganized as a company named HyTest Ltd. and Dr. Severina was appointed as the Managing Director. Under her supervision, HyTest has developed from a startup company into one of the key suppliers of high quality raw materials to the global IVD industry.
Dr. Severina holds a PhD in Biochemistry and Immunochemistry from the Lomonosov Moscow State University.
Maria has been the Managing Director of HyTest ever since it was founded in 1994. Maria started her career as a Senior Researcher at the Moscow Research Institute. From there, she moved to work in the Hybritest project at the University of Turku and was involved in the reorganization of this project into HyTest Ltd. Since its foundation, HyTest has grown from a startup into one of the most important raw material providers for the IVD industry.
Maria holds a PhD in Biochemistry and Immunochemistry from the Lomonosov Moscow State University.
Alexey has been the R&D Director at HyTest Ltd. since 1994. He is also a professor at the Department of Biochemistry at the Lomonosov Moscow State University. Alexey has been studying cardiac markers since the beginning of the 1990s and together with his team at HyTest has been regularly publishing articles in peer reviewed journals. Alexey is a member of two IFCC SD Working Groups: “Standardization of Troponin I (WG-TNI)” and “Standardization of Pregnancy-Associated Plasma Protein A (WG-PAPPA)”.
Alexey holds a PhD in Biochemistry.
Jukka is the Sales and Marketing Director of HyTest. He joined the company in 1999 and prior to working at HyTest he held several managerial positions in companies in different business sectors including life sciences, advertising, real estate and banking.
Jukka holds an MSc in Economics from the Turku School of Economics and Business Administration.
Soozy is the General Manager of HyTest Bio-Tech (Shanghai, China). Prior to joining the company in 2011 she held various different positions at Yarewell and Genetimes.
Soozy holds a BSc in Biotechnology from Zhejiang University and an MBA from Shanghai Jiaotong University.
Yulia is the General Director of HyTest Russia, which is a fully owned subsidiary of HyTest Ltd and was established in 2016. Yulia joined the company in 1996. Prior to the establishment of HyTest Russia, Yulia was the General Director of Bialexa Ltd. She has also been a Senior Scientist and Project Manager at the Moscow Institute of Medical Ecology.
Yulia holds a PhD in Biochemistry from Lomonosov Moscow State University.
Pekka is the head of Business Development at HyTest. He joined the company in 2011 to set up operations in China and establish HyTest Bio-Tech, which is HyTest’s fully owned subsidiary in Shanghai. Prior to joining HyTest, Pekka worked as a Sales and Product Manager at Medix Biochemica and as a Project Manager at Cultor Ltd., as well as a researcher at the University of Helsinki.
Pekka holds an MSc in Biochemistry from the University of Helsinki and an MBA from Henley Business School.
Tatiana is the head of the Production Department at HyTest and she joined the company in 1995. Tatiana has been a Production Director of Bialexa Ltd. and previously worked as a Researcher and Project Manager at the Russian Center of Molecular Diagnostics and Treatment as well as at the Moscow Institute of Medical Ecology.
Tatiana holds a PhD in Biochemistry from the Lomonosov Moscow State University.
Sakke is the Quality Manager at HyTest. She joined the company in 2002 and is responsible for overseeing all regulatory and quality related issues. Prior to joining HyTest, she worked as a Research Assistant at the All Russian Research Institute of Phytopathology.
Sakke holds a BSc in Biotechnology from the Turku University of Applied Sciences
|Stanislav Chakhovich is the CFO (Chief Financial Officer) of HyTest Group. He joined the company in 2018.|
Before joining HyTest Stanislav has worked 17 years in the consulting sphere (in KPMG and PwC), which mostly involved financial due diligence of Finnish, Russian and foreign companies.
Stanislav holds two higher degrees – from Belarusian State Economic University and a Master of Business Administration degree from University of South
Juhana is the Chief Commercial Officer of HyTest since September 2019. He has previously held management positions in various companies in the diagnostic, pharmaceutical, and venture capital industries, including BioFund, Mobidiag, and Plexpress. Prior to joining HyTest he worked as the Business Director for bioreagents at Medix Biochemica.
Juhana holds an MSc in Political Science from the University of Helsinki and an MBA from the Helsinki School of Economics.